SNP Genotyping And Analysis Market Size Worth US$ 46,268.9 Million | 21.9% CAGR By 2027, Owing to Launch of New Products
SNP genotyping is used for gene-wide SNP genotyping, for the analysis of individual SNPs, parentage and pedigree testing, food traceability, breed discrimination, biomarker determination and validation, pharmacogenomics, and forensics.
The global SNP genotyping and analysis market is estimated to account for US$ 11,553.0 Mn in terms of value in 2020 and is expected to reach US$ 46,268.9 Mn by the end of 2027.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/3972
Global SNP Genotyping and Analysis Market: Drivers
Launch of new products is expected to propel growth of the global SNP genotyping and analysis market over the forecast period. For instance, in June 2020, Natera, Inc., the developer of core SNP-based massively multiplexed PCR (mmPCR) technology, launched a novel technique to enhance results from the Prospera donor-derived cell-free DNA (dd-cfDNA) transplant rejection assessment test.
Global SNP Genotyping and Analysis Market: Opportunities
R&D in autoimmune disorders is expected to offer lucrative growth opportunities for players in the global SNP genotyping and analysis market. For instance, in March 2020, researchers from Poznan University of Medical Sciences, Poland, explored the effects of CD16A and CD32A SNPs on the autoimmune response in several autoimmune blistering dermatoses.
Global SNP Genotyping and Analysis Market: Restraints
Unfavorable reimbursement scenario is expected to hinder growth of the market. Genotyping and DNA sequencing tests cost anywhere between US$ 1000 and USD$ 3000. These tests for diseases are currently not covered by insurance companies.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3972
The global SNP genotyping and analysis market was valued at US$ 9,485.2 Mn in 2019 and is forecast to reach a value of US$ 46,268.9 Mn by 2027 at a CAGR of 21.9% between 2020 and 2027. Major factor driving the growth of global SNP genotyping and analysis market during the forecast period include increasing prevalence of genetic disorders, and technological advancement.
SNP Microarray held dominant position in the global SNP genotyping and analysis market in 2019, accounting for 37.9% share in terms of value, followed by Taqman Allelic Discrimination and Others, respectively. Wide applications range is expected to support growth of the segment over the forecast period. As, in diagnosis, microarray can help in identifying genes responsible for a particular disease, diagnostics and prognostics, and pharmacogenomics
Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in October 2018, LGC Limited partnered with Co-Diagnostics, Inc., a molecular diagnostics company, to the use of the company’s CoPrimer technology to test the performance of CoPrimers in multiplexed reactions when locating specific genetic traits in seed products and genetic mutations, including SNP detection.
Major players in the market are also focused on launching new array technologies. For instance, in February 2018, Thermo Fisher Scientific launched the Applied Biosystems Axiom Microbiome Array for simultaneous detection of archaea, bacteria, fungi, protozoa and viruses in human and non-human samples.
Global SNP Genotyping and Analysis Market: Competitive Landscape
Major players operating in the global SNP genotyping and analysis market include, LGC Limited, Fluidigm Corporation, Illumina, Inc., Life Technologies Corporation, PREMIER Biosoft, Thermo Fisher Scientific, and Sequenom, Inc.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/snp-genotyping-and-analysis-market-3240
Global SNP Genotyping and Analysis Market: Key Developments
Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in February 2020, LGC Limited partnered with Swift Biosciences, Inc., a provider of DNA and RNA library preparation kits for Next-Generation Sequencing (NGS), to leverage Swift’s targeted sequencing technology into LGC Limited kits and service offerings for the worldwide AgBio market.
- By Technology
- SNP Microarray
- Taqman Allelic Discrimination
- SNP Pyrosequencing Technologies
- Sequenom Mass-Array MALDI-TOF
- By Application
- Pharmaceuticals and Pharmacogenomics
- Diagnostic Research
- Agricultural Biotechnology
- Breeding and Animal Livestock
- By Region
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire